Akari Therapeutics Partners with WuXi XDC to Advance RNA Splicing ADC Payload
Tuesday, April 07, 2026
Akari Therapeutics has entered into a strategic partnership with WuXi XDC to accelerate the development of its novel antibody-drug conjugate (ADC) payload, PH1, which targets RNA splicing.
Akari is focused on developing next-generation ADC therapies using innovative payloads. Through this collaboration, the company aims to advance its PH1 payload and support further development of its lead candidate, AKTX-101.
AKTX-101 is being developed for the treatment of metastatic urothelial cancer, a condition with significant unmet need, particularly in patients who have progressed after first-line therapies. Current treatment options in later stages remain limited and often provide only modest benefits.
The PH1 payload is designed to disrupt RNA splicing in cancer cells, offering a different mechanism compared to traditional ADC payloads such as microtubule inhibitors or DNA-damaging agents. In addition to direct cytotoxic effects, PH1 may also activate both innate and adaptive immune responses against cancer cells.
Preclinical studies have shown encouraging anti-tumour activity, including tumour regression and complete responses, when compared with other ADC approaches. This highlights the potential of PH1 as part of a new generation of ADC payloads.
Akari plans to advance AKTX-101 into a Phase 1 clinical trial, which is expected to begin in late 2026 or early 2027, subject to regulatory approval. The collaboration with WuXi XDC is expected to support this development and strengthen Akari’s broader strategy to bring novel ADC therapies to patients.
Source: akaritx.com
